Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 18/20 | 0.71 |
| ▸ | PDE4A | P27815 | 16/20 | 0.71 |
| ▸ | PDE4C | Q08493 | 16/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1030283 | 0.87 | PDE4D (0.67) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL1027909 | 0.86 | PDE4D (0.74) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL16651017 | 0.86 | PDE4A (0.69) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL6863990 | 0.84 | PDE4D (0.62) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL19158 | 0.83 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL18095182 | 0.83 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL29349467 | 0.83 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL1031648 | 0.83 | PDE4D (0.80) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL29039838 | 0.82 | PDE4B (0.98) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL7340379 | 0.82 | PDE4D (0.53) | PDE4BPDE4DPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166605-A1 | PROCESS FOR THE PREPARATION OF A PDE4 INHIBITOR | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-05-23 | — | — | US | disclosed |
| US-11981639-B2 | Process for the preparation of a PDE4 inhibitor | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-05-14 | — | — | US | disclosed |
| EP-3587400-B1 | PROCESS FOR THE PREPARATION OF A PDE4 INHIBITOR | CHIESI FARM SPA (IT) | 2024-03-20 | — | — | EP | disclosed |
| US-20230310395-A1 | TOPICAL ROFLUMILAST COMPOSITIONS AND USES THEREOF | SOL-GEL TECHNOLOGIES LTD. (IL) | 2023-10-05 | — | — | US | disclosed |
| US-11352327-B2 | Process for the preparation of a PDE4 inhibitor | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-07 | — | — | US | disclosed |
| US-11352327-B2 | Process for the preparation of a PDE4 inhibitor | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-07 | — | — | US | disclosed |
| EP-3798209-A1 | PROCESS FOR THE PREPARATION OF A CRYSTAL FORM OF A PDE4 INHIBITOR | Chiesi Farmaceutici S.p.A. (IT) | 2021-03-31 | — | — | EP | disclosed |
| EP-3798209-A1 | PROCESS FOR THE PREPARATION OF A CRYSTAL FORM OF A PDE4 INHIBITOR | Chiesi Farmaceutici S.p.A. (IT) | 2021-03-31 | — | — | EP | disclosed |
| US-20210040040-A1 | PROCESS FOR THE PREPARATION OF A PDE4 INHIBITOR | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-02-11 | — | — | US | disclosed |
| US-20210040040-A1 | PROCESS FOR THE PREPARATION OF A PDE4 INHIBITOR | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-02-11 | — | — | US | disclosed |
| US-20150051254-A1 | Treatment of Cognitive Impairment With PDE4 Inhibitor | UNIVERSITEIT MAASTRICHT (NL) | 2015-02-19 | — | — | US | disclosed |
| US-8541456-B2 | Roflumilast for the treatment of diabetes mellitus type 2 | TAKEDA GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-7989431-B2 | 4-{3-[6-Amino-9-(5-cyclopropylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-cyclohexanecarboxylic acid methyl ester; for inflammation, such as organ, tissue or cell transplantation, angioplasty (PCTA), inflammation following ischemia/reperfusion, or grafting | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110136755-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2044023-B1 | DERIVATIVES OF 1-PHENYL-2-PYRIDYNYL ALKYLENE ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMA SPA (IT) | 2011-01-19 | — | — | EP | disclosed |
| US-7671066-B2 | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-03-02 | — | — | US | disclosed |
| EP-2044023-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDYNYL ALKYLENE ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.p.A. (IT) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008006509-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDYNYL ALKYLENE ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015226-A1 | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A.. | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352327-B2 | Process for the preparation of a PDE4 inhibitor | PDE4A, PDE12, PDE4B | PDE4B 3/4885PDE4D 8/4885PDE4A 1/4885 |
| US-20150051254-A1 | Treatment of Cognitive Impairment With PDE4 Inhibitor | PDE4A, PDE4B, PDE4D | PDE4B 2/4885PDE4D 3/4885PDE4A 1/4885 |
| US-20240166605-A1 | PROCESS FOR THE PREPARATION OF A PDE4 INHIBITOR | PDE4A, PDE12, PDE4B | PDE4B 3/4885PDE4D 8/4885PDE4A 1/4885 |
| US-11981639-B2 | Process for the preparation of a PDE4 inhibitor | PDE4A, PDE12, PDE4B | PDE4B 3/4885PDE4D 8/4885PDE4A 1/4885 |
| US-20210040040-A1 | PROCESS FOR THE PREPARATION OF A PDE4 INHIBITOR | PDE4A, PDE12, PDE4B | PDE4B 3/4885PDE4D 8/4885PDE4A 1/4885 |
| US-20110136755-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | ADORA2A, ADORA3, ADORA1 | PDE4B 60/4885PDE4D 58/4885PDE4A 62/4885 |
| US-20080015226-A1 | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE4D 9/4885PDE4A 1/4885 |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | PPARD, PPARA, PPARG | PDE4B 68/4885PDE4D 83/4885PDE4A 46/4885 |
| US-20230310395-A1 | TOPICAL ROFLUMILAST COMPOSITIONS AND USES THEREOF | MMP1, MMP3, MMP11 | PDE4B 204/4885PDE4D 105/4885PDE4A 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.